Safety and Efficacy of Low-Dose Regorafenib Combined with Nivolumab in Patients with Advanced HCC in Progression Beyond Two or More Lines of Tyrosine Kinase Inhibitors: Case Reports and Short Review of the Literature

Background and Aims: A few clinical studies have suggested that low doses of anti-angiogenic molecules might enhance the therapeutic effects of anti-PD1 in HCC and may improve their tolerance. Here, we present case reports of patients treated with low-dose regorafenib combined with nivolumab after the failure of at least two lines of oral chemotherapy.